尊龙时凯

 On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.

Qingdao Baheal Pharma Co., Ltd

 The completed Phase III project has a total construction area of more than 28,000 square meters, covering a comprehensive office building, as well as production facilities and ancillary infrastructure for tablets, granules, hard capsules and other types of dosage forms. Thus, the total area of Qingdao Baheal Pharma has reached 85,600 square meters. After the project is formally put into operation, it will add 5.6 billion tablets/granules production capacity, which will become an essential production platform to support the future development of the enterprise and strongly promote the high-quality development of the enterprise.

 At the ceremony, Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, said that the completion of the Phase III project has enhanced the enterprise's production capacity and intelligence level, and will further strengthen the enterprise's core competitiveness. Taking this relocation as a new starting point, Baheal will continue to uphold the concept of "innovation-driven, quality first", continuously increase the research and development investment, optimize the manufacturing process, provide customers with better products and services, and help more international-level high-end medicines to benefit the majority of patients.

Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, is delivering a speech at the ceremony.

 As an advanced controlled-release formulation R&D and Production platform under Baheal Pharma, Qingdao Baheal Pharma has been constantly focusing on the R&D, production and industrialization of osmotic pumps, micro-pill coating, skeleton tablets and other dosage forms for a long time. The company has passed the U.S. FDA cGMP certification with zero defects for many times, and several products have realized the same production line, with simultaneous application for reimbursement and verification in China and the U.S, which gives the enterprise a significant advantage in the international quality standards construction.

Among them, the self-developed osmotic pump controlled-release dosage form of Dimethyl Metformin Naida has filled the gaps in the controlled-release technology in China. Naida can be taken once a day to stabilize glucose control and has already been listed in China and the United States and included in the National Health Care Directory. In addition, Nifedipine Nate, Duloxetine Nesu and other high-end preparations have also been selected by the National Centralized Procurement, which has effectively improved the accessibility of clinical medication and enhance patients' medication experience.

 In addition to continuing to cultivate the scale production of advanced controlled-release formulation, Qingdao Baheal Pharma has also actively recommended the development and production of innovative medicines. NTB-3119M, a new class 1 anti-tuberculosis drug declared by the Institute of Materia Medica, Chinese Academy of Medical Sciences, has entered the phase I clinical trial, which is expected to become a drug-resistant tuberculosis innovative therapeutic drug independently researched and developed in China, and will bring hope to the patients with drug-resistant tuberculosis. In addition, under the overall strategic guidance of Baheal Pharma Group, Qingdao Baheal Pharma will also build a high-standard and specialized production base for nuclear drug kits, which will help innovative nuclear cold drug products to be transformed and landed.

 In the context of biopharmaceuticals moving towards new quality productivity, the relocation of this project is not only a comprehensive upgrade of Qingdao Baheal Pharma's production abilities, but also a powerful support for the enterprise to plough into the field of high-end preparations in the future and accelerate the industrialization of innovative results. In the future, Qingdao Baheal Pharma will continue to uphold the goal of "optimizing medical scenarios with scientific innovation", strengthen medicine development and process innovation, and contribute to promote local innovative medicines to the world and offer better service for global patients' health.